LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician

[1]  M. Wheeler,et al.  Intrinsic Atrial Myopathy Precedes Left Ventricular Dysfunction and Predicts Atrial Fibrillation in Lamin A/C Cardiomyopathy , 2022, Circulation. Genomic and precision medicine.

[2]  L. Mestroni,et al.  Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study , 2022, Circulation. Genomic and precision medicine.

[3]  Hao Zhang,et al.  New Insights Into the Therapy for Lamin-Associated Dilated Cardiomyopathy , 2022, JACC. Basic to translational science.

[4]  E. Tseng,et al.  2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.

[5]  W. Kraus,et al.  Prevalence and Phenotypic Burden of Monogenic Arrhythmias Using Integration of Electronic Health Records With Genetics , 2022, Circulation. Genomic and precision medicine.

[6]  P. Lambiase,et al.  2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. , 2022, European heart journal.

[7]  K. Lunetta,et al.  LMNA Variants and Risk of Adult-Onset Cardiac Disease. , 2022, Journal of the American College of Cardiology.

[8]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[9]  J. Grizzard,et al.  Cardiac MRI of Hereditary Cardiomyopathy. , 2022, Radiographics : a review publication of the Radiological Society of North America, Inc.

[10]  L. Mestroni,et al.  The response to cardiac resynchronization therapy in LMNA cardiomyopathy , 2022, European journal of heart failure.

[11]  G. Ewald,et al.  Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. , 2022, JAMA.

[12]  M. Vatta,et al.  Points to consider to avoid unfair discrimination and the misuse of genetic information: A statement of the American College of Medical Genetics and Genomics (ACMG). , 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

[13]  A. Bayés‐Genís,et al.  Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. , 2021, Journal of the American College of Cardiology.

[14]  B. Gelb,et al.  Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement From the American Heart Association , 2021, Circulation. Genomic and precision medicine.

[15]  K. Patel,et al.  A DECEPTIVE CASE OF LAMIN A/C-ASSOCIATED CARDIOMYOPATHY , 2021 .

[16]  K. Nikus,et al.  Timing of pacemaker and ICD implantation in LMNA mutation carriers , 2021, Open Heart.

[17]  D. Rader,et al.  Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. , 2021, Cell stem cell.

[18]  Yuchi Han,et al.  Myocardial Tissue Reverse Remodeling after Guideline-directed Medical Therapy in Idiopathic Dilated Cardiomyopathy. , 2020, Circulation. Heart failure.

[19]  L. Tavazzi,et al.  Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry , 2020, ESC heart failure.

[20]  M. Emdin,et al.  Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  Ricardo Henao,et al.  Identification of Undetected Monogenic Cardiovascular Disorders. , 2020, Journal of the American College of Cardiology.

[22]  K. Musunuru,et al.  Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. , 2020, Circulation. Genomic and precision medicine.

[23]  E. Di Pasquale,et al.  The Broad Spectrum of LMNA Cardiac Diseases: From Molecular Mechanisms to Clinical Phenotype , 2020, Frontiers in Physiology.

[24]  Larry Han,et al.  Ventricular Tachycardia in cardiolaminopathy: characteristics and considerations for device programming. , 2020, Heart rhythm.

[25]  M. Link,et al.  2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. , 2019, Heart rhythm.

[26]  R. Porcher,et al.  Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. , 2019, Circulation.

[27]  Howard Y. Chang,et al.  Activation of PDGF Pathway Links LMNA Mutation to Dilated Cardiomyopathy , 2019, Nature.

[28]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2018, Journal of the American College of Cardiology.

[29]  T. Edvardsen,et al.  Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation , 2017, European heart journal.

[30]  L. Mestroni,et al.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms , 2017, Circulation research.

[31]  Y. Pinto,et al.  Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy , 2017, European journal of heart failure.

[32]  W. Stevenson,et al.  Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. , 2016, Journal of the American College of Cardiology.

[33]  M. Perez,et al.  Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association , 2016, Circulation. Cardiovascular genetics.

[34]  L. Maggi,et al.  Skeletal Muscle Laminopathies: A Review of Clinical and Molecular Features , 2016, Cells.

[35]  W. Stevenson,et al.  Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C Cardiomyopathy , 2016, Circulation. Arrhythmia and electrophysiology.

[36]  Nicole M. Johnson,et al.  Who Pays? Coverage Challenges for Cardiovascular Genetic Testing in U.S. Patients , 2016, Front. Cardiovasc. Med..

[37]  H. Sakahara,et al.  Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. , 2014, Magnetic resonance imaging.

[38]  F. Anselme,et al.  Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. , 2013, Heart rhythm.

[39]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[40]  E. Rampersaud,et al.  Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy. , 2013, Journal of cardiac failure.

[41]  A. Zwinderman,et al.  Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. , 2013, International journal of cardiology.

[42]  Nicole M. Johnson,et al.  Genetic testing for dilated cardiomyopathy in clinical practice. , 2012, Journal of cardiac failure.

[43]  A. Zwinderman,et al.  Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. , 2012, Journal of the American College of Cardiology.

[44]  J. Lötjönen,et al.  Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[45]  H. Katus,et al.  Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy , 2010, Heart.

[46]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[47]  P. Rahko,et al.  Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. , 2008, American heart journal.

[48]  Ferhaan Ahmad,et al.  Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. , 2008, Journal of molecular and cellular cardiology.

[49]  I. V. Van Gelder,et al.  High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. , 2007, American heart journal.

[50]  Y. Pinto,et al.  Primary prevention of sudden death in patients with lamin A/C gene mutations. , 2006, The New England journal of medicine.

[51]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[52]  Ueli Aebi,et al.  Intermediate filaments: molecular structure, assembly mechanism, and integration into functionally distinct intracellular Scaffolds. , 2003, Annual review of biochemistry.

[53]  F. Muntoni,et al.  Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy , 1999, Nature Genetics.

[54]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.

[55]  M. Emdin,et al.  CMR-verified interstitial myocardial fibrosis as a marker of subclinical cardiac involvement in LMNA mutation carriers. , 2013, JACC. Cardiovascular imaging.

[56]  H. Crijns,et al.  Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? , 2004, Journal of Molecular Medicine.